South Korea Ex-President Yoon Suk Yeol Sentenced to 30 Years Over Martial Law Plot 
Trump Lawyers Face Scrutiny After Missing Deadline in $10 Billion BBC Defamation Lawsuit 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
U.S. Supreme Court to Review Trump Administration Appeal on Immigrant Detention Without Bond Hearings 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Tabletop particle accelerator could transform medicine and materials science 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump Threatens 100% Tariffs on Countries Imposing Digital Services Taxes on U.S. Tech Firms 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
DOJ Sues Virginia Over Law Enforcement Mask Ban 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
